News & Updates
Filter by Specialty:
Could a single screening colonoscopy prevent CRC?
Results of the NordICC* trial from Europe, presented at the United European Gastroenterology Week (UEG 2022), have hinted at the benefit of a single screening colonoscopy in preventing colorectal cancer (CRC).
Could a single screening colonoscopy prevent CRC?
16 Nov 2022
Depressive symptoms implicated in lung cancer via smoking habits
Individuals with greater depressive symptoms are at risk of developing lung cancer, with the association directly and indirectly attributed to smoking habits, as reported in a study.
Depressive symptoms implicated in lung cancer via smoking habits
16 Nov 2022
Pretreatment sarcopenic assessments help predict gynaecologic cancer outcomes
Pretreatment sarcopenia appears to worsen survival in patients with gynaecologic cancers, such as ovarian (OC), endometrial (EC), and cervical (CC), reports a study. Including this assessment into cancer management may help improve prognosis.
Pretreatment sarcopenic assessments help predict gynaecologic cancer outcomes
15 Nov 2022
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.
HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
14 Nov 2022
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).